CMPX Compass Therapeutics, Inc.
USHealthcareAs of 2026-10-08
Why CMPX matters now
Compass Therapeutics, Inc. (CMPX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.98 with -3.59% on the session and $177.1M in market capitalization; recent performance reads 1-month +11.60% and YTD -62.38%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-18.3M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.1%.
The latest indexable market news headline is "Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Anderman Jonathan filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.02
P/S
0.00
EV/EBITDA
-3.49
DCF Value
$0.12
FCF Yield
-19.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-39.7%
ROA
-33.2%
ROIC
-38.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-18.3M | $-0.10 |
| Q4 2025 | $0.00 | $-15.7M | $-0.09 |
| FY 2025 | $0.00 | $-66.5M | $-0.42 |
| Q3 2025 | $0.00 | $-14.3M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.40
Target (Median)
$9.00
Target Range
$6.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.74
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.